Bubs Australia's U.S. Growth Impresses Bull -- Market Talk
Dow Jones
Mar 30
0023 GMT - Bubs Australia is impressing Shaw & Partners analyst Philip Pepe with its U.S. growth. Pepe tells clients that the infant-formula manufacturer's U.S. distribution reach looks strong given that it only entered the country in 2022. Bubs, which specializes in goat-milk formulas, has been operating on a discretionary basis pending permanent access approval by the U.S. Food and Drug Administration. Pepe reckons this permanent approval should arrive soon. Shaw & Partners keeps a buy rating and A$0.18 target price on the stock, which is flat at A$0.10. (stuart.condie@wsj.com)
(END) Dow Jones Newswires
March 29, 2026 20:23 ET (00:23 GMT)
Copyright (c) 2026 Dow Jones & Company, Inc.
At the request of the copyright holder, you need to log in to view this content
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.